rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Donald Notman

Chief Operating Officer

Company insider

Files Form 4 as: Chief Operating Officer, Ocular Therapeutix.

Every Form 4 they filed

In numbers

Trades disclosed
36
Buys
3
Sells
10
Bought
$109K
Sold
$671K
Companies
1
Companies where not an officer
0
First trade
2 Oct 2017
Last trade
31 Aug 2026
Last filed
2 Sep 2026

Companies traded

Where they are an officer
OCUL Ocular TherapeutixOfficer · Biotechnology · last 31 Aug 20263 buys · 10 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
31 Aug 2026filed 2 Sep 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$11K1,099 at $10.24filing
31 Aug 2026filed 2 Sep 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$11K1,099 at $10.24filing
12 Feb 2026filed 17 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$103K11,446 at $9.04filing
12 Feb 2026filed 17 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$103K11,446 at $9.04filing
4 Feb 2026filed 4 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$52K6,035 at $8.54filing
4 Feb 2026filed 4 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$52K6,035 at $8.54filing
2 Feb 2026filed 4 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$50K5,455 at $9.14filing
2 Feb 2026filed 4 Feb 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$50K5,455 at $9.14filing
2 Jan 2026filed 6 Jan 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code A—79,112 at $0.00filing
2 Jan 2026filed 6 Jan 2026OCUL Ocular Therapeutixoption or derivative · BiotechnologySEC FORM 4 Code A—240,932 at $0.00filing
2 Jan 2026filed 6 Jan 2026OCUL Ocular Therapeutixoption or derivative · BiotechnologySEC FORM 4 Code A—240,932 at $0.00filing
2 Jan 2026filed 6 Jan 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code A—79,112 at $0.00filing
2 Sep 2025filed 4 Sep 2025OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$13K1,066 at $12.43filing
11 Feb 2025filed 13 Feb 2025OCUL Ocular Therapeutixoption or derivative · BiotechnologySEC FORM 4 Code A—344,115 at $0.00filing
11 Feb 2025filed 13 Feb 2025OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code A—115,000 at $0.00filing
4 Feb 2025filed 4 Feb 2025OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$87K11,119 at $7.81filing
31 Jan 2025filed 4 Feb 2025OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$49K6,301 at $7.84filing
29 Aug 2024filed 3 Sep 2024OCUL Ocular Therapeutixoption or derivative · BiotechnologySEC FORM 4 Code A—33,602 at $0.00filing
29 Aug 2024filed 3 Sep 2024OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code A—11,034 at $0.00filing
5 Feb 2024filed 6 Feb 2024OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$30K6,212 at $4.86filing

Sectors

Health Care13

Buys in green, sells in red, by the company’s sector.

Related people

Todd AndermanChief Legal Officer · Chief Legal Officer at Ocular Therapeutix, filing Form 4 there in the last year
Jeffrey S. HeierChief Scientific Officer · Chief Scientific Officer at Ocular Therapeutix, filing Form 4 there in the last year
Peter KaiserChief Development Officer · Chief Development Officer at Ocular Therapeutix, filing Form 4 there in the last year
Pravin DugelDirector and Officer · Director and Officer at Ocular Therapeutix, filing Form 4 there in the last year
Sanjay NayakChief Strategy Officer · Chief Strategy Officer at Ocular Therapeutix, filing Form 4 there in the last year